U.S. Markets open in 5 hrs 10 mins

Holding(s) in Company


Holding(s) in Company

December 4, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Shire plc
(LEI:54930005LQRLI2UXRQ59)
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer  
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights  
Other (please specify)iii:  
3. Details of person subject to the notification obligationiv
Name Susan Kilsby (Chairman of Shire plc and proxy holder)
City and country of registered office (if applicable)  
4. Full name of shareholder(s) (if different from 3.)v
Name Third parties holding ADRs on behalf of the person identified in box 3 and shareholders appointing (i) the Chairman of Shire plc as proxy and (ii) a designate of Shire plc as proxy.
City and country of registered office (if applicable)  
5. Date on which the threshold was crossed or reachedvi: December 3, 2018
6. Date on which issuer notified (DD/MM/YYYY): December 4, 2018
7. Total positions of person(s) subject to the notification obligation
  % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached 7.65 %   7.65 % 915,888,124
Position of previous notification (if
applicable)
       



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix % of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
JE00B2QKY057
(Shire plc Ordinary Shares of 5 pence each)
  70,089,867   7.65 %
         
         
SUBTOTAL 8. A 70,089,867 7.65 %
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
         
         
         
    SUBTOTAL 8. B 1    
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
           
           
           
      SUBTOTAL 8.B.2    
 

 

 


9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii X
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
 
Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
       
       
       
       
       
 
10. In case of proxy voting, please identify:
Name of the proxy holder Susan Kilsby (Chairman of Shire plc)
The number and % of voting rights held 70,063,380 / 7.65%
The date until which the voting rights will be held The conclusion of Shire plc’s General Meeting to be held on December 5, 2018, or any adjournment thereof.
 
11. Additional informationxvi
The number of indirect voting rights includes 70,063,380 voting rights, being the maximum number of discretionary proxy votes held by the Chairman of Shire plc pursuant to proxies received in respect of the resolution to be considered by shareholders at the Shire plc General Meeting to be held on December 5, 2018. These voting rights will expire immediately upon the conclusion of the General Meeting, or any adjournment thereof. The appointment of a proxy shall not preclude a shareholder of Shire plc from attending and voting in person at the General Meeting.


Place of completion Dublin, Ireland
Date of completion December 4, 2018

For further information please contact:

Investor Relations    
Christoph Brackmann christoph.brackmann@shire.com +41 41 288 41 29
Sun Kim sun.kim@shire.com +1 617 588 8175
Scott Burrows scott.burrows@shire.com +41 41 288 4195
     
Media    
Katie Joyce kjoyce@shire.com  +1 781 482 2779
     

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
 
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.

www.shire.com